Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.2200-0.0100 (-0.45%)
At close: 03:59PM EST
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Evaxion Biotech Highlights Promising Data From Personalized Cancer Immunotherapy

    Evaxion Biotech A/S (NASDAQ: EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. "We are thrilled to announce promising interim data from the first eight patients...All patients demonstrated a specific T-cell immune response induced by the trea

  • GlobeNewswire

    Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

    COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected

  • GlobeNewswire

    Evaxion Announces Third Quarter 2022 Financial Results and Business Update

    Per Norlén, M.D., PhD. joined Evaxion as Chief Executive Officer in October Enrollment of the first patient in our global Phase 2b clinical trial of EVX-01 Increased strategic focus on clinical lead oncology assets and partneringCash and cash equivalents of $17.9 million sufficient to fund operations into mid-2023 COPENHAGEN, Denmark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company), a clinical-stage biotechnology company specializing in the develo

Advertisement
Advertisement